The Ethics of Characterizing Difference: Guiding Principles on Using Racial
Categories in Human Genetics
By Sandra Soo-Jin Lee et. al.,
Genome Biology
| 07. 15. 2008
Abstract
We are a multidisciplinary group of Stanford faculty who propose ten principles to guide the use of racial and ethnic categories when characterizing group differences in research into human genetic variation.
Open letter
Since the completion of the Human Genome Project, research focused on human genetic variation, including differences among groups, has intensified. This focus has rekindled debates about the connection between genetic (DNA-level) traits and human 'racial' difference [1-5]. Scholars are divided on the question of whether racial categorization is an appropriate means of organizing potentially useful genetic data or a pernicious reification of historically destructive typologies [6,7]. To explore these issues, faculty from the humanities, social sciences, life sciences, law and medicine at Stanford University convened over the past few years to engage in an extended interdisciplinary dialog. The initial meeting consisted of a two-day workshop in 2003 that developed into an ongoing faculty research seminar sponsored by the Stanford Humanities Center, Affymetrix Corporation, the Mellon Foundation and the Research Institute of the Center for Comparative Studies on Race and Ethnicity. This seminar series, which continued for...
Related Articles
By Tomoko Otake, The Japan Times | 04.09.2024
A decade ago, researcher Haruko Obokata caused a sensation when she published two papers in the journal Nature, in which she claimed that she had discovered a way to create stem cells easily using the so-called STAP method.
With STAP...
By Eric Schmidt, TIME | 04.16.2024
Imagine a world where everything from plastics to concrete is produced from biomass. Personalized cell and gene therapies prevent pandemics and treat previously incurable genetic diseases. Meat is lab-grown; enhanced nutrient grains are climate-resistant. This is what the future could...
By Tristan Manalac, BioSpace | 04.02.2024
Verve Therapeutics has suspended enrollment in the Phase Ib Heart-1 study evaluating its lead gene editing program VERVE-101 following a serious adverse event, the company announced Tuesday.
A patient, who received a 0.45-mg/kg dose of VERVE-101, developed a grade 3...
By Jorge Barrera and Rachel Houlihan, CBC | 04.09.2024
A Canadian DNA laboratory knowingly delivered prenatal paternity test results that routinely identified the wrong biological fathers — ruling out the real dads — and left a trail of shattered lives around the globe, a CBC News investigation has found...